Comparing Clinical Outcomes of Steroid-Sparing Therapy With Rituximab Versus Rituximab Alone in Pemphigus

March 2024 | Volume 23 | Issue 3 | e97 | Copyright © March 2024


Published online February 14, 2024

Danielle E. Mustin MEnga, Emily F. Cole MD MPHb, Rebecca Leibowitz BSa, Ron J. Feldman MD PhDc

aEmory University School of Medicine, Atlanta, GA  
bDepartment of Dermatology, Duke University Medical Center, Durham, NC 
cDepartment of Dermatology, Emory School of Medicine, Atlanta, GA 

CONCLUSION

Our results indicate that the use of SST with rituximab dosing did not improve clinical outcomes related to time to remission, reduction in prednisone dosing, or relapse.  While the cohort on SST had a longer disease duration, it is not clear whether continuing SST with rituximab dosing confers any additional benefit. These data provide further evidence for not adding and/or discontinuing SST with rituximab therapy in most patients with pemphigus. Limitations include a high proportion of patients with moderate disease, a retrospective analysis, and a single academic center. Further clinical trials are needed to confirm the appropriate rituximab dosing schedule for induction of long-term remission.

DISCLOSURES

The authors have no conflicts of interest to declare.

REFERENCES

 
  1. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389: 2031-40. 
  2. Murrell DF, Pena S, Joly P, et al. Diagnosis and management of pemphigus: Recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82:575-85e1. 
  3. Wang HH, Liu CW, Li YC, Huang YC. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta dermato-venereologica. 2015;95(8):928-932. https://doi.org/10.2340/00015555-2116 
  4. Maley A, Warren M, Haberman I, et al. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol. 2016;74:835-40. 
  5. Keeley JM, Bevans SL, Jaleel T et al. Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients. J Dermatolog Treat. 2019;30:340-5. 
  6. Murrell DF, Dick S, Ahmed AR et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58:1043-6. 
  7. Boulard C, Duvert Lehembre S, Picard-Dahan C et al. Calculation of cut-off values based on the autoimmune bullous skin disorder intensity score (ABSIS) and pemphigus disease area index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol. 2016;175:142-9. 
  8. Shimizu T, Takebayashi T, Sato Y et al. Grading criteria for disease severity by pemphigus disease area index. J Dermatol. 2014;41:969-73. 
  9. Hebert V, Boulard C, Houivet E, et al. Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. J Invest Dermatol 2019;139:31-7. 

AUTHOR CORRESPONDENCE

Ron J. Feldman MD PhD ron.j.feldman@emory.edu
Close Menu